Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations-A Social Epidemiology Counterargument

Am J Med. 2020 Oct;133(10):e541-e543. doi: 10.1016/j.amjmed.2020.04.017. Epub 2020 May 20.

Authors

Miguel Cainzos-Achirica¹, Usama Bilal²

Affiliations

¹ Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins Medicine and University, Baltimore, Md. Electronic address: mcainzos@jhu.edu.
² Urban Health Collaborative; Department of Epidemiology and Biostatistics, Drexel Dornsife School of Public Health, Philadelphia, Penn.

No abstract available

Publication types

Editorial

MeSH terms

Antihypertensive Agents / therapeutic use*
Aspirin / therapeutic use
Cardiovascular Diseases / prevention & control*
Delivery of Health Care*
Diet
Drug Combinations
Drug Monitoring
Environmental Pollution
Health Literacy
Health Services Accessibility*
Healthcare Financing
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Implementation Science
Medically Underserved Area*
Medication Adherence
Platelet Aggregation Inhibitors / therapeutic use*
Poverty
Primary Prevention
Sedentary Behavior
Social Determinants of Health*
Social Support
Tobacco Use

Substances

Antihypertensive Agents
Drug Combinations
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Platelet Aggregation Inhibitors
Aspirin

Grants and funding

DP5 OD026429/OD/NIH HHS/United States